Veeva Unveils eSource App; Goldman Sachs Issues Sell Rating With $215 Target
On January 29, Veeva launched eSource, a SiteVault application designed to streamline clinical trial data capture and improve data quality. On January 13, Goldman Sachs cut its rating to Sell with a $215 price target, citing challenges sustaining high-teens growth against rising competition from Salesforce.
1. eSource Application Launch
On January 29, Veeva introduced eSource as part of its SiteVault platform to eliminate manual clinical trial workflows. The digital solution captures patient data at research sites in real time, aiming to boost data integrity and drive higher contract renewals from pharmaceutical and biotech customers.
2. Goldman Sachs Rating Cut
On January 13, Goldman Sachs downgraded Veeva to Sell and set a $215 price target, pointing to slowing growth in core offerings. The firm highlighted limited visibility on revenue from newer products and intensifying competition from Salesforce’s Life Sciences Cloud.
3. BioMarin Partnership Expansion
On January 8, Veeva expanded its long-term enterprise agreement with BioMarin Pharmaceutical, extending software, data and consulting services. The renewed deal is structured to enhance BioMarin’s R&D agility and improve engagement with healthcare providers and patients.
4. Competitive and Growth Outlook
While Veeva’s R&D solutions show promise, sustaining high-teens revenue growth toward its 2030 goals depends on adoption of new products and differentiation in a crowded market. Strategic partnerships and product innovation will be key drivers of valuation and market share over the coming years.